SIREN : 843846916
SPFPL PHARMA CHALAIS is a French company founded 7 years ago, specialized in the sector Activités des sociétés holding. Based in BARBEZIEUX-SAINT-HILAIRE (16300), this company of category PME shows in 2024 a revenue of 46 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 46 200 € | 45 600 € | 45 600 € | 19 000 € |
| Net income | 124 989 € | 142 777 € | 125 145 € | 17 310 € |
| EBITDA | 18 386 € | 15 977 € | 20 182 € | -82 572 € |
| Net margin | 270.5% | 313.1% | 274.4% | 91.1% |
In 2024, SPFPL PHARMA CHALAIS achieves revenue of 46 k€. Over the period 2021-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +34.5%. Vs 2023: +1%. After deducting consumption (0 €), gross margin stands at 46 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 18 k€, representing 39.8% of revenue. Positive scissor effect: EBITDA margin improves by +4.8 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 125 k€, i.e. 270.5% of revenue. This profit can be retained or distributed to shareholders.
46 200 €
46 200 €
18 386 €
1 769 €
124 989 €
39.8%
The debt ratio (= Financial debt / Equity x 100) stands at 261%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 25%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 12.9 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 306.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
261.108%
24.768%
306.506%
12.895
62.4%
In 2024, the debt ratio of SPFPL PHARMA CHALAIS (261.11) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of SPFPL PHARMA CHALAIS (24.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of SPFPL PHARMA CHALAIS (12.89) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 2.12. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 101.4x. Operating income very largely covers interest expenses: high safety margin.
2.125
101.398
In 2024, the liquidity ratio of SPFPL PHARMA CHALAIS (2.12) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of SPFPL PHARMA CHALAIS (101.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 30 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 25 days. The company must finance 5 days of gap between collections and payments. WCR is negative (-2264 days): operations structurally generate cash. Notable WCR improvement over the period (-1347%), freeing up cash.
-290 523 €
30 j
25 j
0 j
-2264 j
Based on 54 transactions of similar company sales
in 2024,
the value of SPFPL PHARMA CHALAIS is estimated at
89 112 €
(range 35 878€ - 273 006€).
With an EBITDA of 18 386€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SPFPL PHARMA CHALAIS with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of SPFPL PHARMA CHALAIS in 2024 is 46 k€.
Yes, SPFPL PHARMA CHALAIS generated a net profit of 125 k€ in 2024.
The headquarters of SPFPL PHARMA CHALAIS is located in BARBEZIEUX-SAINT-HILAIRE (16300), in the department Charente.
The tax return of SPFPL PHARMA CHALAIS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SPFPL PHARMA CHALAIS operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.